130 related articles for article (PubMed ID: 3170130)
1. Mitoxantrone in combination with prednimustine in treatment of unfavorable non-Hodgkin lymphoma.
Landys KE
Invest New Drugs; 1988 Jun; 6(2):105-13. PubMed ID: 3170130
[TBL] [Abstract][Full Text] [Related]
2. Prednimustine, mitoxantrone (PmM) vs cyclophosphamide, vincristine, prednisone (COP) for the treatment of advanced low-grade non-Hodgkin's lymphoma. German Low-Grade Lymphoma Study Group.
Unterhalt M; Herrmann R; Tiemann M; Parwaresch R; Stein H; Trümper L; Nahler M; Reuss-Borst M; Tirier C; Neubauer A; Freund M; Kreuser ED; Dietzfelbinger H; Bodenstein H; Engert A; Stauder R; Eimermacher H; Landys K; Hiddemann W
Leukemia; 1996 May; 10(5):836-43. PubMed ID: 8656680
[TBL] [Abstract][Full Text] [Related]
3. Treatment of low-grade non-Hodgkin's lymphoma by cytoreductive chemotherapy with prednimustine/mitoxantrone followed by interferon alpha-2b maintenance: results of a clinical phase II study.
Hiddemann W; Unterhalt M; Koch P; Nahler M; van de Loo J
Semin Oncol; 1990 Dec; 17(6 Suppl 10):20-3. PubMed ID: 2259919
[TBL] [Abstract][Full Text] [Related]
4. Second-line chemotherapy in human immunodeficiency virus-related non-Hodgkin's lymphoma: evidence of activity of a combination of etoposide, mitoxantrone, and prednimustine in relapsed patients.
Tirelli U; Errante D; Spina M; Gastaldi R; Nigra E; Nosari AM; Magnani G; Vaccher E
Cancer; 1996 May; 77(10):2127-31. PubMed ID: 8640681
[TBL] [Abstract][Full Text] [Related]
5. Mitoxantrone in combination with etoposide and prednimustine in patients older than 70 years with unfavorable non-Hodgkin's lymphoma: a prospective study in 52 patients.
Tirelli U; Zagonel V; Sorio R; Errante D; Talamini R; Carbone A; Monfardini S
Semin Hematol; 1994 Apr; 31(2 Suppl 3):13-22. PubMed ID: 8073302
[No Abstract] [Full Text] [Related]
6. Mitoxantrone, prednimustine, and vincristine for elderly patients with aggressive non-Hodgkin's lymphoma.
Yau JC; Germond C; Gluck S; Cripps C; Verma S; Burns BF; Koski TM; Lister DC; Goss GD
Am J Hematol; 1998 Oct; 59(2):156-60. PubMed ID: 9766801
[TBL] [Abstract][Full Text] [Related]
7. A prospective study of a new combination chemotherapy regimen in patients older than 70 years with unfavorable non-Hodgkin's lymphoma.
Tirelli U; Zagonel V; Errante D; Serraino D; Talamini R; De Cicco M; Carbone A; Monfardini S
J Clin Oncol; 1992 Feb; 10(2):228-36. PubMed ID: 1732423
[TBL] [Abstract][Full Text] [Related]
8. alpha Interferon maintenance therapy in patients with low-grade non-Hodgkin's lymphomas after cytoreductive chemotherapy with prednimustine and mitoxantrone.
Hiddemann W; Unterhalt M; Koch P; Nahler M; Herrmann R; van de Loo J
Eur J Cancer; 1991; 27 Suppl 4():S37-9. PubMed ID: 1799474
[TBL] [Abstract][Full Text] [Related]
9. Salvage chemotherapy with mitoxantrone, fludarabine, cytarabine, and cisplatin (MIFAP) in relapsing and refractory lymphoma.
Hänel M; Kröger N; Kroschinsky F; Birkmann J; Hänel A; Herbst R; Naumann R; Friedrichsen K; Ehninger G; Zander AR; Fiedler F
J Cancer Res Clin Oncol; 2001; 127(6):387-95. PubMed ID: 11414199
[TBL] [Abstract][Full Text] [Related]
10. New aspects in the treatment of advanced low-grade non-Hodgkin's lymphomas: prednimustine/mitoxantrone versus cyclophosphamide/vincristine/prednisone followed by interferon alfa versus observation only--a preliminary update of the German Low-Grade Lymphoma Study Group.
Hiddemann W; Unterhalt M; Koch P; Nahler M; Herrmann R
Semin Hematol; 1994 Apr; 31(2 Suppl 3):32-5. PubMed ID: 8073307
[No Abstract] [Full Text] [Related]
11. Prednimustine and mitoxantrone (PmM) in patients with low-grade malignant non-Hodgkin's lymphoma (NHL), chronic lymphocytic leukemia (CLL), and prolymphocytic leukemia (PLL).
Freund M; Wunsch-Zeddies S; Schäfers M; Wysk J; Seidel I; Hiddemann W; Hanauske AR; Link H; Schmoll HJ; Poliwoda H
Ann Hematol; 1992 Feb; 64(2):83-7. PubMed ID: 1554799
[TBL] [Abstract][Full Text] [Related]
12. Mitoxantrone-DHAP with GM-CSF: an active but myelosuppressive salvage therapy for relapsed/refractory aggressive non-Hodgkin's lymphoma.
Haq R; Sawka CA; Franssen E; Berinstein NL
Leuk Lymphoma; 1999 Nov; 35(5-6):527-36. PubMed ID: 10609790
[TBL] [Abstract][Full Text] [Related]
13. Prednimustine combined with mitoxantrone and 5-fluorouracil for first and second-line chemotherapy in advanced breast cancer.
Samonigg H; Stöger H; Kasparek AK; Schmid M; Dusleag J; Pfeiffer K; Smola M; Steindorfer P; Lechner P
Cancer Chemother Pharmacol; 1991; 27(6):477-80. PubMed ID: 2013118
[TBL] [Abstract][Full Text] [Related]
14. Mitozantrone and prednimustine in the treatment of advanced breast cancer--a toxic regimen with low activity.
O'Brien ME; Eccles DM; Allen SG; Knight G; Rodger A; Chetty U; Smyth JF; Leonard RC
Cancer Chemother Pharmacol; 1991; 28(5):402-4. PubMed ID: 1914086
[TBL] [Abstract][Full Text] [Related]
15. Reduced-dose cladribine (2-CdA) plus mitoxantrone is effective in the treatment of mantle-cell and low-grade non-Hodgkin's lymphoma.
Rummel MJ; Chow KU; Karakas T; Jäger E; Mezger J; von Grünhagen U; Schalk KP; Burkhard O; Hansmann ML; Ritzel H; Bergmann L; Hoelzer D; Mitrou PS
Eur J Cancer; 2002 Sep; 38(13):1739-46. PubMed ID: 12175690
[TBL] [Abstract][Full Text] [Related]
16. Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ).
Zinzani PL; Tani M; Pulsoni A; Gobbi M; Perotti A; De Luca S; Fabbri A; Zaccaria A; Voso MT; Fattori P; Guardigni L; Ronconi S; Cabras MG; Rigacci L; De Renzo A; Marchi E; Stefoni V; Fina M; Pellegrini C; Musuraca G; Derenzini E; Pileri S; Fanti S; Piccaluga PP; Baccarani M
Lancet Oncol; 2008 Apr; 9(4):352-8. PubMed ID: 18342572
[TBL] [Abstract][Full Text] [Related]
17. The rationale of therapy with mitoxantrone in non-Hodgkin's lymphoma. The Non-Hodgkin's Lymphoma Co-operative Study Group, (NHLCSG) Italy.
Chisesi T
Leuk Lymphoma; 1993 Jan; 9(1-2):63-9. PubMed ID: 8477203
[TBL] [Abstract][Full Text] [Related]
18. Mitoxantrone, etoposide, cytarabine and prednisone as salvage therapy for refractory non-Hodgkin lymphoma (NHL) and alternated with CHOP in previously untreated patients with NHL.
Merk K; Ideström K; Johansson B; Kimby E; Lindemalm C; Osby E; Björkholm M
Eur J Haematol; 1991 Jan; 46(1):33-7. PubMed ID: 1988304
[TBL] [Abstract][Full Text] [Related]
19. Long-term results of a multicentre randomised, comparative phase III trial of CHOP versus CNOP regimens in patients with intermediate- and high-grade non-Hodgkin's lymphomas. Novantrone International Study Group.
Bezwoda W; Rastogi RB; Erazo Valla A; Diaz-Maqueo JC; Pavlovsky S; Morioka H; Resegotti L; Rueckle H; Somoza N; Moreno-Nogueira JA
Eur J Cancer; 1995 Jun; 31A(6):903-11. PubMed ID: 7646919
[TBL] [Abstract][Full Text] [Related]
20. Mitoxantrone and high-dose cytarabine as salvage therapy for refractory non-Hodgkin's lymphoma.
Ho AD; del Valle F; Rückle H; Schwammborn J; Schlimok G; Hiddemann W; Meusers P; Thiel E; Dörken B; Hunstein W
Cancer; 1989 Oct; 64(7):1388-92. PubMed ID: 2776103
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
